Zhongtai Securities released a research report on April 23 stating that it maintains the purchase rating of Nootech Biotech (688076.SH). The main reasons for the rating include: 1) performance is higher than the median forecast, and advantages in the peptide field continue to be realized, and it is expected that it will continue to maintain a high growth trend; 2) self-selected products, mainly peptides and specialty APIs, continue to grow rapidly, and small-molecule CDMOs are gradually recovering. (Mainichi Keizai Shimbun)
中泰证券4月23日发布研报称，维持诺泰生物（688076.SH）买入评级。评级理由主要包括：1）业绩高于预告中值，多肽领域优势持续兑现，有望持续维持高增态势；2）多肽、特色原料药为主的自主选择产品持续高速增长，小分子CDMO呈逐步恢复态。（每日经济新闻）
Zhongtai Securities released a research report on April 23 stating that it maintains the purchase rating of Nootech Biotech (688076.SH). The main reasons for the rating include: 1) performance is higher than the median forecast, and advantages in the pept
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.